The Netherlands Pharmacovigilance Centre Lareb received 8 reports of gastric polyps in association with proton pump inhibitors (PPIs). Proton pump inhibitors (PPIs) are used for the treatment of gastroesophageal reflux disease, gastric and duodenal ulcer, Zollinger-Ellison syndrome and as prophylaxis (NSAIDs).
Polyps are abnormal growths in mucous membranes and commonly found in the colon, stomach, uterus and nose. There are several types of gastric polyps, including fundic gland polyps (FGPs). Especially FGPs have been associated with the use of PPIs. Long-term use is a possible risk factor and there is a potential plausible mechanism. As described in the literature and based on the positive dechallenges in some of the described reports, FGPs can reduce after withdrawal of the PPI. The association is well described in the literature, however still inconclusive.
More information can be found here.